1. Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
- Author
-
Zhang W, Wang Y, He J, Xu Y, Chen R, Wan X, Shi W, Huang X, Xu L, Wang J, and Zha X
- Subjects
- Humans, Female, Docetaxel therapeutic use, Albumin-Bound Paclitaxel therapeutic use, Neoadjuvant Therapy, Retrospective Studies, Paclitaxel therapeutic use, Albumins, Taxoids therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Nanoparticles
- Abstract
Purpose: There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluate the efficacy of different taxanes on neoadjuvant systemic treatment (NST) in breast cancer., Methods: Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR), breast pathological complete response (breast-pCR), and axillary pathological complete response (axillary-pCR) for in-depth analysis and discussion., Results: The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant among all the taxanes in the axillary-pCR rate., Conclusion: Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer., Competing Interests: Declaration of competing interest The authors have no relevant financial or non-financial interests to disclose., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF